GLP-1s and Testosterone: Weight Loss, Lean Mass, and Health

GLP-1 medicines are used for type 2 diabetes and weight management; tirzepatide acts on both GIP and GLP-1 receptors. Claims that these drugs universally destroy testosterone do not match the evidence. Weight loss can improve testosterone levels in some men with obesity, while preserving strength and adequate nutrition remains an important part of treatment.

This article examines testosterone findings during incretin treatment, what body-composition studies mean by lean mass, and how to discuss muscle preservation with your care team.

What the Research Shows About GLP-1s and Testosterone

Studies in men with obesity, diabetes, or functional hypogonadism have reported testosterone increases during GLP-1 treatment. These findings involve specific populations and do not predict every man’s response.

Published studies have examined GLP-1 medicines and testosterone in men with obesity or metabolic disease. The populations, drugs, and designs differ, so pooled associations should not be presented as a uniform response to every medicine.

A 2025 conference report analyzed records from 110 men receiving incretin therapies. The proportion with normal total testosterone rose from 53% to 77%; those numbers were not percentage increases in testosterone concentration. This observational finding is useful, but it does not isolate a direct drug effect from weight loss or other changes.

Obesity can affect testosterone through several pathways, including changes in SHBG, metabolic health, and reproductive signaling. Fat tissue also contains aromatase. Weight loss can improve this picture, but the mechanism is broader than reducing testosterone-to-estrogen conversion alone.

The useful conclusion is specific: some men with obesity have improved testosterone during treatment. The evidence does not support a universal increase or a universal decline.

So What's the Real Concern?

Weight loss can include both fat and lean tissue. Preserving strength and function matters, but lean-mass loss is not proof that treatment will cause a later testosterone decline.

In the STEP 1 body-composition substudy, semaglutide reduced fat mass and lean mass, while the proportion of body weight made up of lean tissue increased. DXA lean mass includes water, organs, and other non-fat tissue as well as muscle. It should not be described as kilograms of skeletal muscle lost.

Skeletal muscle has important functions during weight loss:

• Supports movement, strength, and physical independence.

• Drives basal metabolic rate — losing muscle means burning fewer calories at rest

• Contributes to glucose disposal and metabolic health.

• Works with bone to support movement and loading.

• Preserves functional strength — critical for healthy aging and quality of life

A percentage of weight loss recorded as lean mass cannot be equated directly with muscle loss. Strength, physical performance, nutrition, and the clinical context help determine whether the change is concerning. There is no established muscle–testosterone feedback loop that predicts hormones will fall after GLP-1 treatment.

The GLP-1 + Sarcopenia Connection

Sarcopenia involves low muscle strength with reduced muscle quantity or quality. Testosterone can affect muscle, but low muscle mass does not by itself establish a cause of testosterone deficiency. Assessment should focus on strength, function, and relevant health conditions.

Testosterone contributes to muscle maintenance, and treatment can increase lean mass in men with deficiency. Effects on strength and physical function vary. That relationship does not establish a muscle-loss-to-testosterone feedback loop or justify testosterone treatment in men without an appropriate diagnosis.

During substantial weight loss, issues worth monitoring include:

• Reduced muscle mass

• Low strength or physical performance, particularly in older or vulnerable adults.

• Inadequate protein or energy intake.

• Difficulty maintaining normal activities or training.

These are reasons to build a nutrition and activity plan into treatment, not evidence that its hormonal benefits inevitably reverse.

The Weight Regain Problem Makes It Worse

Weight regain can occur after stopping weight-management medication. In the STEP 1 extension, participants regained about two-thirds of the weight they had previously lost during the year after semaglutide withdrawal. The finding supports planning ongoing care rather than stopping without a maintenance strategy.

Regain does not follow one fixed pattern of fat, muscle, or testosterone change. A practical follow-up plan considers:

• Weight and waist changes during treatment.

• Strength, daily function, and nutritional intake.

• The reason for stopping and alternative treatment options.

• Changes in appetite and eating patterns.

• Whether physical activity and strength training remain sustainable.

• New or persistent symptoms that justify clinical review.

A planned transition helps protect progress. The evidence does not establish that men who stop GLP-1 treatment inevitably end up with more fat, less muscle, or lower testosterone than before treatment.

The Honest Concern Beyond the Hype

A retrospective TriNetX study compared 3,094 non-diabetic men with obesity prescribed semaglutide with matched controls. The recorded outcome of new ED diagnosis or PDE5-inhibitor prescription was 1.47% versus 0.32%; testosterone-deficiency diagnoses were 1.53% versus 0.80%. These were associations in health records, not randomized proof of causation.

Observational findings can reflect differences in the patients, prescribing, or follow-up as well as medication effects. New sexual symptoms deserve a discussion with the prescriber; they are not a reason to assume the medication is the cause or stop it on your own.

How to Support Strength and Health During Treatment

Make nutrition and physical function part of the treatment plan:

• Use regular resistance exercise matched to your experience and ability. A safe, progressive program matters more than a fixed heavy-training schedule.

• Plan adequate protein with your clinician or dietitian, especially if appetite is low. Needs depend on age, body size, activity, and conditions such as kidney disease.

• Avoid letting appetite suppression turn into inadequate nutrition. Review persistent nausea, very low intake, or rapid loss of strength with the care team.

• Use hormone testing when symptoms or clinical findings justify it. There is no universal requirement for a full testosterone panel at baseline, three months, and six months.

• Track symptoms. Energy, libido, morning erections, gym performance, cognitive function. If any decline meaningfully, investigate.

• Review supplements with your prescriber. Correcting a nutrient deficiency can be appropriate, but testosterone supplements have not been established as a way to preserve muscle or hormonal function during GLP-1 treatment.

After GLP-1: The Reload Problem

If you and your prescriber decide to stop or change treatment, plan the transition:

• Continue a sustainable resistance-training program.

• Maintain protein intake. Don't drop protein just because appetite returns.

• Plan for slow caloric reintroduction. Don't immediately return to pre-GLP-1 eating patterns.

• Track strength and function as well as weight. Body-composition testing can be useful in selected circumstances, but it does not directly measure every aspect of muscle health.

• Review persistent fatigue, sexual symptoms, or reduced function rather than assuming a supplement will protect hormone levels.

The Integrated Approach

Medication, nutrition, exercise, and follow-up work together. The practical priorities are:

• GLP-1s for fat loss and metabolic improvement

• Strength training for muscle preservation

• Adequate protein for muscle protein synthesis

• Sleep and stress management for recovery and wellbeing.

• Supplements only when they fit an identified nutritional or clinical need.

Testostemem is a testosterone-and-memory support formula with a disclosed ingredient label. Its ingredient research is available on our science page. It is not established as protection against GLP-1-related muscle loss, and supplements should be reviewed with the clinician managing your medication.

Frequently Asked Questions About GLP-1s and Testosterone

Do GLP-1s lower testosterone?

Studies in men with obesity have reported testosterone increases during treatment, often alongside weight loss. Responses vary, and the available evidence does not establish that all GLP-1 medicines either raise or lower testosterone in every user.

How much muscle do you lose on GLP-1s?

The amount varies. Body-composition studies often report lean mass, which includes more than skeletal muscle. Do not interpret a lean-mass percentage as a direct measure of muscle loss; strength and function provide additional context.

Can GLP-1s cause sexual side effects?

A retrospective semaglutide study reported more ED-related diagnoses or prescriptions and testosterone-deficiency diagnoses than in matched controls. It cannot establish that the drug caused those outcomes. Discuss new symptoms with your prescriber.

How do I preserve muscle while on a GLP-1?

Use an appropriate resistance-training program, maintain adequate nutrition and protein, and review loss of strength or very low intake with your care team. The plan should fit your medical history and treatment goals.

What happens to testosterone when you stop a GLP-1?

There is no single predictable testosterone response. Weight regain is common after withdrawal, but a fixed progression to sarcopenic obesity or testosterone below baseline has not been established. Plan follow-up before changing treatment.